---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-001500"
form_type: "8-K"
ticker: "PHIO"
cik: "0001533040"
company_name: "Phio Pharmaceuticals Corp."
filed_at: "2026-01-20T23:59:59+00:00"
generated_at: "2026-05-16T09:32:10.573272+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Phio reports 70% ORR in cSCC from PH-762 trial; 10 of 14 responders had 100% clearance

## Summary
- 22 cutaneous carcinoma patients treated across 5 dose cohorts; no dose-limiting toxicities reported.
- Among 20 cSCC patients, 14 responders; 10 complete (100% clearance), 2 major/near clear, 2 partial.
- PH-762 well tolerated with 20-fold dose escalation; safety follow-up data expected in Q2 2026.
- One Merkel cell carcinoma patient had partial response; no disease progression in any patient.

## SEC filing metadata
- accession: 0001437749-26-001500
- form_type: 8-K
- ticker: PHIO
- cik: 0001533040
- company_name: Phio Pharmaceuticals Corp.
- filed_at: 2026-01-20T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1533040/000143774926001500/0001437749-26-001500-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1533040/000143774926001500/phio20260113_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-001500
- JSON: https://secwatch.observer/filing/0001437749-26-001500.json
- Plain text: https://secwatch.observer/filing/0001437749-26-001500.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.